USPTO issues 3rd patent to Myriad aiding in bringing MRD assay to market

Myriad Genetics announced that the United States Patent and Trademark Office has issued a third patent that will strengthen its ability to deliver a tumor-informed, high-definition, molecular residual disease or MRD assay to market. U.S. patent no. 12,104,212, entitled “Personalized Methods for Detecting Circulating Tumor DNA,” demonstrates Myriad’s continued efforts to advance its MRD strategy on multiple fronts. The claims of the patent cover proprietary methods that generate ultra-sensitive detection of tumor-specific mutations in circulating tumor DNA or ctDNA ….to enable highly sensitive and specific tumor-informed, sequencing-based MRD assays such as Precise .”The issuance of this third MRD patent supports Myriad’s efforts to establish a proprietary and differentiated MRD assay that tracks up to thousands of tumor-specific variants, making it capable of detecting ctDNA at lower levels than other products in the market today,” said Paul J. Diaz, President and CEO, Myriad Genetics. ”